Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Clinical Trials

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Phase 2

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Trifluridine/tipiracil
Drug: Tislelizumab
Drug: Bevacizumab

First Posted Date: 2025-03-04

Last Posted Date: 2025-03-04

Lead Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Target Recruit Count: 140

Registration Number: NCT06856837

Locations: 🇦🇹
SCRI CCCIT Ges.m.b.H., Salzburg, Austria
🇦🇹
Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹
Noe LGA Gesundheit Thermenregion GmbH, Wiener Neustadt, Austria

and more 20 locations

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: Envafolimab
Drug: Fruquintinib

First Posted Date: 2025-01-24

Last Posted Date: 2025-01-24

Lead Sponsor: First Affiliated Hospital of Fujian Medical University

Target Recruit Count: 40

Registration Number: NCT06791083

Locations: 🇨🇳
The First Affiliated Hospital of Fujian Medical University, FuZhou, Fujian, China

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Phase 2

Recruiting

Conditions: Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Fruquintinib

First Posted Date: 2025-01-14

Last Posted Date: 2025-01-14

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 69

Registration Number: NCT06774222

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, China

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Fruquintinib
Drug: Sintilimab
Drug: Chidamide

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-20

Lead Sponsor: Dai, Guanghai

Target Recruit Count: 46

Registration Number: NCT06685276

Locations: 🇨🇳
China PLAGH, Beijing, China

Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Neoplasms

Interventions: Drug: Fruquintinib
Drug: Tislelizumab
Radiation: Radiotherapy

First Posted Date: 2024-10-17

Last Posted Date: 2024-10-17

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 67

Registration Number: NCT06646588

Locations: 🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

Not Applicable

Recruiting

Conditions: MSS Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Ningbo Medical Center Lihuili Hospital

Target Recruit Count: 30

Registration Number: NCT06613113

Locations: 🇨🇳
Kaitai Liu, Ningbo, Zhejiang, China

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3

Recruiting

Conditions: Advanced Endometrial Cancer

Interventions: Drug: fruquintinib
Drug: paclitaxel
Biological: sintilimab
Drug: doxorubicin

First Posted Date: 2024-09-04

Last Posted Date: 2025-01-07

Lead Sponsor: Hutchmed

Target Recruit Count: 412

Registration Number: NCT06584032

Locations: 🇨🇳
Beijing Obstetrics and Gynecology Hospital, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Phase 4

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2024-08-20

Last Posted Date: 2025-05-04

Lead Sponsor: Takeda

Target Recruit Count: 78

Registration Number: NCT06562543

Locations: 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Ironwood Cancer and Research Centers, Gilbert, Arizona, United States

and more 41 locations

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Not Applicable

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Cadonilimab
Radiation: SBRT

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-13

Lead Sponsor: Liu Huang

Target Recruit Count: 80

Registration Number: NCT06551207

Locations: 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib or Regorafenib
Drug: Sintilimab
Drug: Fruquintinib

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 68

Registration Number: NCT06543836

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy